Sunny Pharmtech

Sunny Pharmtech Enterprise Value

The Enterprise Value (EV) of Sunny Pharmtech (6676.TWO) as of Nov 22, 2026 is 2.63 B TWD. In the previous year, Enterprise Value (EV) was 2.49 B TWD — a change of 5.27% (higher).

Enterprise Value

2.63 BTWD

YoY

5.27%

Last updated:

Enterprise Value (EV) of Sunny Pharmtech is 2024 2.63 B TWD. Enterprise Value (EV) of Sunny Pharmtech was 2023 2.49 B TWD. It decreases by 5.27% higher compared to the previous year.

The Sunny Pharmtech Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
2.54 B TWD
Jan 1, 2019
2.43 B TWD
Jan 1, 2020
2.52 B TWD
Jan 1, 2021
2.46 B TWD
Jan 1, 2022
2.65 B TWD
Jan 1, 2023
2.49 B TWD
Jan 1, 2024
2.63 B TWD
The Sunny Pharmtech Enterprise Value history
YEAREnterprise ValueYoY
2.63 BTWD+5.27%
2.49 BTWD-6.00%
2.65 BTWD+7.78%
2.46 BTWD-2.35%
2.52 BTWD+3.57%
2.43 BTWD-4.12%
2.54 BTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunny Pharmtech Stock analysis

What does Sunny Pharmtech do? Sunny Pharmtech Inc develops, manufactures, and markets generic and 505(b)2 drug products, primarily targeting the United States market. The company's main products include lectin drug complex (LDC) anesthesia analgesic ointment, neurofibrillary tangle (NFT) anti-urinary tract infection capsules, anti-mitochondrial antibody (AMA) hemostatic lozenges, cyclosporine A (CYA) injections for anemia, and campto (CPT) gynecological injections. These products are sold directly to customers in the United States, generating revenue through pharmaceutical sales. The company focuses on developing and commercializing specialized drug formulations, with its product portfolio centered on LDC, NFT, AMA, CYA, and CPT branded medications. Sales are concentrated in the United States, where the firm's generic and 505(b)2 drug products are marketed to healthcare providers and pharmacies. Revenue is derived from the direct sale of these pharmaceutical products to U.S. customers. Sunny Pharmtech Inc's business model relies on the development and marketing of its proprietary drug formulations, including LDC, NFT, AMA, CYA, and CPT products, which are sold to the United States market. The company's revenue stream is generated through the sale of these branded pharmaceutical products to U.S. healthcare institutions and retail pharmacies. Sunny Pharmtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunny Pharmtech stock

Enterprise Value (EV) of Sunny Pharmtech is 2.63 B TWD in 2024.

Enterprise Value (EV) of Sunny Pharmtech changed from 2.49 B TWD to 2.63 B TWD, representing a 5.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Sunny Pharmtech since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s TWD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' TWD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Sunny Pharmtech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Sunny Pharmtech

All Key Metrics — Sunny Pharmtech